140 related articles for article (PubMed ID: 12959183)
1. Oncogenic pathways implicated in ovarian epithelial cancer.
Nicosia SV; Bai W; Cheng JQ; Coppola D; Kruk PA
Hematol Oncol Clin North Am; 2003 Aug; 17(4):927-43. PubMed ID: 12959183
[TBL] [Abstract][Full Text] [Related]
2. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
3. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
Asselin E; Mills GB; Tsang BK
Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
[TBL] [Abstract][Full Text] [Related]
4. Roles of LPA in ovarian cancer development and progression.
Pua TL; Wang FQ; Fishman DA
Future Oncol; 2009 Dec; 5(10):1659-73. PubMed ID: 20001802
[TBL] [Abstract][Full Text] [Related]
5. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
6. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
[TBL] [Abstract][Full Text] [Related]
7. TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling.
Liu L; Wu N; Wang Y; Zhang X; Xia B; Tang J; Cai J; Zhao Z; Liao Q; Wang J
J Exp Clin Cancer Res; 2019 Feb; 38(1):106. PubMed ID: 30819230
[TBL] [Abstract][Full Text] [Related]
8. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways.
Chang MC; Chen CA; Chen PJ; Chiang YC; Chen YL; Mao TL; Lin HW; Lin Chiang WH; Cheng WF
Biochem J; 2012 Mar; 442(2):293-302. PubMed ID: 21999204
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib controls the epithelial‑mesenchymal transition of ovarian cancer cells via EGF and the CD44‑HA signaling pathway in a cell type‑dependent manner.
Park GB; Ko HS; Kim D
Mol Med Rep; 2017 Aug; 16(2):1826-1836. PubMed ID: 28627617
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analysis of ovarian cancer cells during epithelial-mesenchymal transition (EMT) induced by epidermal growth factor (EGF) reveals mechanisms of cell cycle control.
Grassi ML; Palma CS; Thomé CH; Lanfredi GP; Poersch A; Faça VM
J Proteomics; 2017 Jan; 151():2-11. PubMed ID: 27394697
[TBL] [Abstract][Full Text] [Related]
11. [Expression of aFGF in ovarian epithelial cancer and its signal transduction pathway].
Zhang Y; Sun LG; Shang H; Gao H; Yu HY; Gao SM; Liu N
Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(11):976-80. PubMed ID: 12899800
[TBL] [Abstract][Full Text] [Related]
12. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
Li H; Zeng J; Shen K
Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744
[TBL] [Abstract][Full Text] [Related]
13. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival.
Fu X; Li Y; Alvero A; Li J; Wu Q; Xiao Q; Peng Y; Hu Y; Li X; Yan W; Guo K; Zhou W; Wang Y; Liu J; Zhang Y; Mor G; Wen J; Yin G
Oncotarget; 2016 Dec; 7(49):80633-80654. PubMed ID: 27811362
[TBL] [Abstract][Full Text] [Related]
15. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
16. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.
Tanyi JL; Morris AJ; Wolf JK; Fang X; Hasegawa Y; Lapushin R; Auersperg N; Sigal YJ; Newman RA; Felix EA; Atkinson EN; Mills GB
Cancer Res; 2003 Mar; 63(5):1073-82. PubMed ID: 12615725
[TBL] [Abstract][Full Text] [Related]
17. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
[TBL] [Abstract][Full Text] [Related]
19. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.
Bagnato A; Rosanò L
Cells Tissues Organs; 2007; 185(1-3):85-94. PubMed ID: 17587812
[TBL] [Abstract][Full Text] [Related]
20. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells.
Thant AA; Nawa A; Kikkawa F; Ichigotani Y; Zhang Y; Sein TT; Amin AR; Hamaguchi M
Clin Exp Metastasis; 2000; 18(5):423-8. PubMed ID: 11467775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
